Traders should monitor for follow-up announcements after the AACR presentations, particularly if data support IND filing for TNX-1700. However, no material near-term catalysts are expected given the early stage of development.
Price Chart
Executive Summary
Tonix Pharmaceuticals announced upcoming presentations at the AACR Annual Meeting 2026 on its preclinical immuno-oncology programs, including data on TNX-1700, an investigational fusion protein for gastric and colorectal cancer. The presentations highlight preclinical research but do not include clinical trial results or regulatory approvals. The company remains in the pre-IND stage for these candidates.
Key Facts
- Tonix will present one oral and two poster presentations at AACR 2026 on its preclinical immuno-oncology programs.
- TNX-1700, a TFF2-albumin fusion protein, is in preclinical development for gastric and colorectal cancer and remains in pre-IND stages.
- No clinical data, regulatory decisions, or financial results were disclosed.
- Presentations focus on mechanism of action, in vitro characterization of anti-BTLA antibodies, and pharmacokinetics in animal models.
- TNX-1700 is in-licensed from Columbia University; collaboration includes scientific co-authorship.
Financial Impact
No immediate financial impact; preclinical data unlikely to affect near-term revenue or expenses
Risk Factors
- Preclinical results may not translate to clinical efficacy.
- No guarantee that TNX-1700 will advance to clinical trials or receive regulatory approval.
- Limited market interest in early-stage immuno-oncology assets without human data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257693 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $5.73 | awaiting T+20 | — | $5.39 (−5.85%) |
Oct 15, 2026 12d ago | 8-K | $6.42 | awaiting T+20 | — | $5.39 (−15.97%) |
Oct 2, 2026 24d ago | 8-K | $8.07 | awaiting T+20 | — | $5.39 (+33.15%) |
Sep 22, 2026 5w ago | 8-K | $10.59 $5.78 | ▼ −45.42% | ▼ −44.86% | $5.39 (−49.06%) |
Sep 8, 2026 7w ago | 8-K | $13.16 $7.70 | ▼ −41.49% | ▼ −43.46% | $5.39 (−59.00%) |
Aug 10, 2026 11w ago | 8-K | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.15%) |
Aug 10, 2026 11w ago | Press Release | $12.59 $13.16 | ▲ +4.53% | ▲ +5.44% | $5.39 (−57.15%) |
Aug 3, 2026 12w ago | 8-K | $10.67 $14.10 | ▲ +32.15% | ▲ +30.91% | $5.39 (−49.44%) |
Jul 27, 2026 13w ago | Press Release | $10.37 $12.45 | ▲ +20.06% | ▲ +16.76% | $5.39 (−47.97%) |
Jul 13, 2026 15w ago | 8-K | $11.71 $12.59 | ▲ +7.56% | ▲ +4.38% | $5.39 (−53.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers